Immuneonco Biopharmaceuticals (Shanghai) Inc.

Tianma Micro-Electronics Co., Ltd.

Shanghai Tianma Am-Oled Co., Ltd.

Agora Lab, Inc.

Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd.

Honeywell International Inc.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Shanghai Hansoh Biomedical Co., Ltd.

Psa Automobiles Sa

Song Li

Wenzhi Tian

Dianze Chen

Bo Wu

Liyuan Luo

Jianyuan Feng

Jimeng Zheng

Huiqin Guo

Jun Wang

Gang Liu

Jun Wu

Sheng Huang

Bojia Lv

Yidong Su

Yekun Gao

Xiaopo Chen

Ning Yu

Zi Ye Wang

Ke Kai Yang

Rong Hua Peng

Sen Gen Chen

Cui Ping Liu

Brunet Manquat David

A nitrogen-containing ring derivative regulator, a preparation method therefor and use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a G protein-coupled receptor regulator in the treatment or prevention of central nervous system diseases and/or mental diseases.

Benzothiophene derivative regulator, preparation method therefor and use thereof

A real-time communication software application for generating spatial audio with uniform reverberation in a real-time communication session is performed by an electronic communication device. The application is adapted to remove the reverberation of recorded speech signals from far-end participants by the dereverberation approach, render the direct sound parts by filtering the output signals by head-related transfer functions of desired directions, generate reverberant sound parts by convolving the output signals from with uniform room impulse responses or an artificial reverberator, and combine direct and reverberant sound components to generate spatialized speech signals. When speakers and listeners are located in two virtual conference rooms, the reverberation of the two rooms are coupled. The reverberant sound parts are then generated by convolving the output signals and coupled RIRs from the two rooms.

System for generating spatial audio with uniform reverberation in real-time communication

A computer-implemented method for generating spatial audio with uniform reverberation in a real-time communication session is performed by a real-time communication software application running on an electronic communication device. The method includes removing the reverberation of recorded speech signals from far-end participants by the dereverberation approach, rendering the direct sound parts by filtering the output signals by head-related transfer functions of desired directions, generating reverberant sound parts by convolving the output signals from with uniform room impulse responses or an artificial reverberator, combining direct and reverberant sound components to generate spatialized speech signals. When speakers and listeners are located in two virtual conference rooms, the reverberation of the two rooms are coupled. The reverberant sound parts are then generated by convolving the output signals and coupled RIRs from the two rooms.

System and method for generating spatial audio with uniform reverberation in real-time communication

Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.

Antibodies binding CD24, preparation and use thereof

The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.

Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereof

The present application provides a recombinant fusion protein containing an anti-PD-L1 antibody or an antibody fragment thereof, with each paratope of the anti-PD-L1 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain variable region or a light chain variable region constituting the paratope, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over-expression of CD47 and/or PD-L1 using the recombinant fusion protein.

Recombinant fusion proteins targeting CD47 and PD-L1, preparation and use thereof

Disclosed is an antibody that specifically binds CD70, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD70 signaling using the antibody or antigen binding portion thereof are also provided.

Antibodies binding CD70, preparation and use thereof

The present disclosure provides a recombinant fusion protein containing an extracellular Ig-like domain of a signal-regulator protein (SIRP), linked via a linker, to a paratope of an Ig-like anti-HER2 antibody at the N-terminus of a heavy chain or a light chain constituting the paratope. The present disclosure also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over-expression of CD47 and/or HER2.

Recombinant bifunctional protein targeting CD47 and HER2

Provided is a bi-functional fusion protein as well as its preparation method and use. The bi-functional fusion protein is composed of a monoclonal anti-human CD20 antibody linked to a first extracellular domain of human SIRP&#x3b1;. It is shown in in vitro tests that the bi-functional fusion protein is capable of binding to human CD20 and CD47 simultaneously, thus killing CD20+ tumor cells via antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and is also capable of blocking CD47-SIRP&#x3b1; interaction such that macrophages are activated to attack tumor cells. The bi-functional fusion protein has evident anti-tumor activities.

Recombinant bi-functional fusion protein and use thereof

Disclosed is a recombinant protein containing 1) an anti-PD-L1 antibody heavy chain and an anti-PD-L1 antibody light chain, which two are linked by a disulfide bond to bind PD-L1, and 2) an extracellular Ig-like domain of a vascular epithelial growth factor receptor (VEGFR), linked via a linker to the N-terminus or C-terminus of the heavy chain or the light chain, wherein the recombinant protein is capable of binding PD-L1, VEGF and Fc receptor simultaneously. Also disclosed are a recombinant antibody containing two recombinant proteins of the disclosure, a polynucleotide encoding the recombinant protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of VEGF and/or PD-L1 using the recombinant protein.

Recombinant protein targeting PD-L1 and VEGF

The present invention provides a recombinant fusion protein containing an anti-PD-L1 antibody, with at least one paratope of the anti-PD-L1 antibody linked via a linker to an extracellular Ig-like domain of a signal-regulator protein (SIRP) at N-terminus of a heavy chain or a light chain, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47 and/or PD-L1 using the recombinant protein.

Recombinant fusion protein containing an anti-PD-L1 antibody

Systems and methods of security enhancement in a security panel are provided. Some systems can include a security system and a keyfob. The security system can identify the keyfob, receive user input identifying a valid user pass code, and transmit the valid user pass code to the keyfob. The keyfob can save the received valid user pass code, receive user input identifying a first user input mechanism, receive user input identifying a sequence of user input mechanisms, determine whether the received sequence of user input mechanisms corresponds to the saved valid user pass code, and responsive to a valid correspondence, transmit a signal to the security system with instructions to execute an action associated with the first user input mechanism.

System and method of security enhancement in a security panel

An Organic Light Emitting Diode (OLED) display device and a manufacturing method thereof, the OLED display device including: a substrate; a pixel definition layer located on the substrate, wherein a plurality of pixel units arranged together are defined in the pixel definition layer, at least one of the pixel units comprises at least one first sub pixel, at least one second sub pixel and at least one third sub pixel, and the third sub pixel comprises at least two third secondary sub pixels; a first organic light emitting layer arranged in each of the at least one first sub pixel, a second organic light emitting layer arranged in each of the at least one second sub pixel, and third organic light emitting layers arranged in the at least two third secondary sub pixels of the at least one third sub pixel.

Organic light emitting diode display device and manufacturing method thereof

A circuit is disclosed. The circuit includes a first transistor, to respond to a first scanning signal and to transmit a first voltage, a first capacitor, to store the first voltage, and an organic light emitting diode. The circuit also includes a second transistor, to provide a current to the organic light emitting diode, a third transistor, to respond to a second scanning signal and to transmit a first potential signal to the second transistor, and a fourth transistor, to respond to the first scanning signal and to form a diode connection of the second transistor. The circuit also includes a fifth transistor, to respond to a third scanning signal and to transmit a second signal voltage to the second transistor, and a sixth transistor, to respond to a light emitting scanning signal, and to output the current to the organic light emitting diode.

Growing community of inventors

Shanghai, China

Song Li